Introduction
Interest in cytotoxic chemotherapy regimes in hormone refractory prostate cancer (HRPC) is re-emerging, with encouraging response rates to combination regimes seen in phase II studies. (Petrylak et al. Semin Urol Oncol 2002; 20:31-35) . However, results may be confounded by concommitant steroid use for nausea prophylaxis. The regime of Epirubicin, cisplatin and 5-Fluorouracil (ECF) has shown response rates of over 40% in prostate cancer in small series although renal and auditory toxicity have been problematic. The substitution of carboplatin for cisplatin (ECarboF) is an attractive option and has been successfully implemented in breast cancer, (Bonnefoi et al, Ann Oncol 2000; 11(12) :1557) but may increase myelosuppression. We wished to establish the effi cacy and tolerability of the ECarboF regime in a large group of patients with hormone refractory prostate cancer, and to ensure that any benefi t related to the cytotoxic regime rather than to co-administered steroids.
Materials and Methods
Patients with recurrent or metastatic HRPC who had failed fi rst-line hormonal therapy, and who were either symptomatic or asymptomatic with 3 successive PSA rises were eligible. Previous hormone therapy was continued with the exception of non-steroidal anti-androgens, and a change in hormonal therapy was not permitted. All patients were performance status 0-2 with no previous cytotoxic therapy. Patients received combination intravenous chemotherapy with epirubicin 50 mg/m 2 , carboplatin (AUC 5) given 4 weekly, and 5-FU 450 mg/m 2 on day 1 and 15. If patients had previously received 2nd-line hormonal therapy using steroids, routine anti-nausea prophylaxis with dexamethasone was given. Otherwise steroids were omitted from the anti-emetic regime unless intractable vomiting developed or patients developed a concurrent spinal-cord compression. PSA and symptomatic response were assessed together with toxicity data. A maximum of 8 cycles were given. Results 80 patients were entered over a 6 year period, with median age of 64 years. Patients received a median of 5 cycles with dose reductions or delay seen in 57%. The majority pf patients (30% Group 1, 65% Group 2) were in relatively good prognostic groups according to the Fossa categories. (Fossa et al. Ann Oncol 1992; 3:361-366) . 21 patients had not previously received steroids as part of their anti-tumour management, and of these, 7 required the addition of dexamethasone during chemotherapy treatment due to nausea or neurological symptoms. Neutropenic sepsis rate was low (8.7%), with non haematological grade 3-4 toxicity occurring in 27.5%. 36/80 patients (45%) showed PSA and / or radiological responses. 41/63 (65%) patients who had been symptomatic prior to treatment showed a symptomatic benefi t from treatment. The median duration of response was 9.5 months (range 7-17 months) with a median survival of 9.2 months (range 1-29 months). Of the 21 patients who had been steroidnaïve, 7 patients required dexamethasone for persistent emesis or neurological deterioration and 14 did not. The response duration and median survival was similar in both of these steroid-naïve subgroups, showing that the response to treatment was due to the effect of the cytotoxic chemotherapy. 1 year survival was 40% with 11% alive at 2 years. Discussion Chemotherapy for HRPC has been historically disappointing but interest in new combinations of cytotoxic therapy is growing. Response rates of up to 74% with estramustine and docetaxel have been reported (Petrylak et al. Semin Urol Oncol 2002; 20:31-35) but the use of steroids in combination with cytotoxic therapy confounds the results due to the anti-tumour effect of steroids. We demonstrate the effi cacy and manageable toxicity of the outpatient combination ECarboF regime in selected patients with HRPC and advocate further evaluation including quality of life data and overall survival. 
Development of Quantitative RT-PCR for Molecular Staging in Prostate Cancer Using Established and Novel Markers in

NW Clarke
Introduction
The natural history of prostate cancer (CaP) is diffi cult to predict. The key to appropriate treatment is detection of extraprostatic disease. We have developed a quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) assay using a combination of established and novel molecular markers to detect small numbers of circulating prostatic cells in peripheral blood (PB) and bone marrow (BM).
Materials and Methods
Five nucleotide primers and probes were designed and optimised (PSA, prostate specifi c membrane antigen (PSMA), prostate stem cell antigen (PSCA), human kallikrein 2 (HK2) and DD3). In vitro assay sensitivity was calibrated using dilutions of LNCaP cells in female PB. The PAXgene blood RNA system was optimised for PB and BM collection, storage and RNA isolation. Marker expression was quantifi ed in serial dilutions and limits of detection determined using qRT-PCR. DD3 was quantifi ed using a plasmid construct. Paired PB and BM samples were then assayed from patients with well characterised CaP and compared with disease free controls.
Results
All fi ve gene products were detected and quantifi ed in LNCaP cells. In vitro limits of detection were 1 LNCaP cell/10 5 nucleated cells (PSA and PSMA), 1:10 4 (PSCA), 1:10 3 (HK2) and 10 plasmid copies/100ng of cDNA (DD3). Gene products were absent in all controls. PCR product identity was confi rmed by both gel electrophoresis and nucleotide sequencing. 83 CaP patients and 20 control subjects have been sampled to date (45 have localised disease and 38 locally advanced or metastatic disease, 13 of these being hormone independent), for whom qRT-PCR profi les are being generated.
Conclusions
We have standardised a qRT-PCR assay for PB and BM in CaP using established and novel markers. This enables generation of stage and outcome specifi c molecular profi les in men with CaP.
Introduction
We report early outcome data for patients who underwent prostate brachytherapy (BXT) with up to 5 years follow up.
Methods
Of 404 patients we have treated to date, we report biochemical outcomes for 302 patients with >9m follow up (mean follow up 24.8m; range 9-61m). 
Materials and Methods
We have used quantitative reverse transcription real time PCR (q-RT-PCR) to measure the mRNA levels of VDR and three known co-repressors (SMRT, NCoR1 and Alien) in normal prostate epithelial cells (PrEC), cancer cell lines (LNCaP, and primary cultures of prostate cancer (n = 12) and normal peripheral zone (n = 8). These approaches were complemented by Western immunoblotting for co-repressors. Co-repressor complexes were targeted with histone deacetylase (HDAC) inhibitors (either dietary-derived short chain fatty acid compounds such as sodium butyrate (NaB) or therapeutic agents such as Trichostatin A (TSA)) in combination with nuclear receptor ligand, and molecularly by small interfering RNA approaches (siRNA). The effects of these treatments were explored by proliferation and apoptosis studies, microarray approaches and target gene regulation by Q-RT-PCR.
Results
We found signifi cantly elevated SMRT levels in cancer cell lines correlated with reduced antiproliferative sensitivity to 1,25(OH) 2 D 3 . For example, PC-3 and DU-145 prostate cancer cell lines have 1.8 and 2 fold increase in SMRT mRNA relative to normal PrEC cells (p<0.05); elevated SMRT protein was confi rmed. Similarly 8/12 primary tumour samples had elevated SMRT mRNA levels (mean 4.2 fold increase); generally NCoR1 and Alien were not as commonly elevated (3/12 and 2/12 respectively). Interestingly SMRT and VDR levels Abstracts British Prostate Group were positively correlated in the tumour material (p<0.001). Furthermore the antiproliferative action of 1,25(OH) 2 D 3 can be dramatically and signifi cantly enhanced by co-treatment with low doses of HDAC inhibitors such as either NaB or TSA to induce apoptosis in prostate cancer cell lines. cDNA microarray and gene expression studies in PC-3 cells after 6 hr co-treatment of 1,25(OH) 2 D 3 plus TSA confi rmed the unique and signifi cant up regulation of a number of antiproliferative target genes including MAPK-APK2 and GADD45 alpha. Supportively primary cancer cultures with elevated SMRT demonstrated suppressed GADD45 alpha induction compared to matched normal controls. Subsequently we knocked-down SMRT levels in PC-3 cells using siRNA which resulted in a 95% reduction in the basal levels of SMRT mRNA after 72 hr, and found that GADD45 alpha induction by 1,25(OH) 2 D 3 alone became very signifi cantly enhanced. Conclusions These data demonstrate that the nuclear receptor co-repressor SMRT is commonly elevated in prostate cancer cells and drives transcriptional and therefore cellular insensitivity to ligands such as 1,25(OH) 2 D 3 . This molecular lesion will most probably have a broad impact on the signalling capacity of a wide range of nuclear receptors. Individual molecular diagnostic profi ling of early stage cancers will highlight individuals who would respond to targeting the co-repressor complex either through pharmacological or nutritional intervention.
Introduction
Androgen ablation is an accepted method of treatment for metastatic prostate cancer until the disease undergoes a transition to the hormone refractory form. This transition cannot be explained simply by loss of the androgen receptor as the majority of hormone refractory tumours maintain androgen receptor (AR) expression. Many cancers even overexpress the androgen receptor protein by amplifi cation of the gene or by other means. Understanding role of the androgen receptor in prostate has been inhibited in the past by the limitation of suitable model systems. Experimental work has relied heavily on the LNCaP cell line or on transient transfection, often into non-prostate cell lines. We have developed novel non-malignant prostate epithelial cell lines that stably express wild type human AR.
Materials and Methods
Novel cell lines were established by selecting stable transfectants from PNT1A prostate epithelial cells transfected with an episomal plasmid encoding a human AR cDNA. Androgen receptor protein expression and stabilisation in response to androgens were assessed by western blotting. Translocation of the AR in response to steroidal or antiandrogenic compounds was visualised by immunocytochemistry and the transactivation capacity of the receptor was demonstrated by the ability to activate a promoter-EGFP reporter construct (PSA/Pb-EGFP). Results Our cell lines, PNT1A.ARWT115 and PNT1A.ARWT124 respectively show a basal level of androgen receptor expression at approximately 30-50% of that seen in LNCaP. This level is increased in response to 10nM or 100nM dihydrotestosterone and reverts to basal levels upon addition of 100nM bicalutamide. Immunocytochemistry shows that the receptor is cytoplasmic in the absence of hormone with translocation to the nucleus in the presence of steroid hormones or antiandrogens. The time course of androgen response suggests that the primary events such as translocation and activation of transcription are initiated within 4-6 hours rather than 1-2 days when androgen response has conventionally been measured. Translocation occurs most rapidly in response to cyproterone acetate; but DHT, β-estradiol and bicalutamide all cause translocation on a comparable time scale. Once in the nucleus the receptor is functional as demonstrated by transactivation of the reporter construct PSA/ Pb-EGFP.
Conclusion
This system represents a unique model of androgen receptor function in prostate epithelium. Wild type human androgen receptor shows stable expression; AR protein is stabilised by androgens and is functional as shown by the capacity to transactivate an androgen responsive reporter construct. Translocation to the nucleus occurs in response to steroid hormones as would be expected. However, translocation is already maximal within 8 hours, this presents the possibility of an immediate early androgen response that might previously have been overlooked. Finally this model has been established in non-malignant cells whose growth and survival is unaffected by exogenous androgens although the response pathway is present. These cells will allow a dissection of malignancy from androgen response.
Introduction
Hormone refractory prostate cancer is a signifi cant clinical problem with few therapeutic options. The molecular mechanisms underlying the development of hormone refractory prostate cancer are poorly understood and research into mechanisms of hormone resistance is essential. Here we investigate the role of HER2 and the MAP kinase pathway in the development of hormone refractory prostate cancer.
Materials and Methods
A cohort of 50 patients with paired histological specimens obtained before and after the development of hormone refractory prostate cancer was retrieved from the archives with full clinical and biochemical follow-up. Tumour protein expression of HER2, Phosphorylated HER2, Raf-1, phosphorylated Raf-1, c-Jun, phosphorylated c-Jun and c-Fos were analysed by immunohistochemistry. Protein expression was scored by two independent observers using a weighted histoscore method.
Results
In the hormone sensitive tissue only HER2 expression correlated with Raf-1 expression (p=0.035) and expression of none of the protein investigated correlated with time to relapse. However increased HER2 expression at hormone relapse was associated with a signifi cant shorter overall survival (p=0.0058) using Kaplan Meier analysis. In hormone refractory specimens not only did HER2 and Raf-1 correlate (p=0.05), but their activated forms (phosphorylated HER2 and phosphorylated Raf-1) also correlated (p=0.007). In addition a down stream target of the MAP kinase pathway, activated c-Jun, which forms the transcription factor AP-1 when bound to c-Fos, also correlates with activated Raf-1 expression (p= 0.028 respectively). Kaplan Meier survival analysis demonstrates that patients who expressed high levels of activated c-Jun (histoscore of >100) in their hormone refractory specimen survive for a signifi cantly shorter length of time from point of relapse than those with low activated c-Jun expression (histoscore of <100)(p=0.0229).
Abstracts
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Introduction
We previously reported six germline BRCA2 mutations in a set of 263 prostate cancer patients diagnosed at < 55 years (Edwards et al 2003) . The patients' ages at diagnosis (years) and mutations were as follows: (A): 44, IVS17-1g>c; (B): 47, 7084del5; (C): 48, 2558insA; (D): 52, 8525delC; (E): 52, 6710del4; (F): 53, 7772insA. We have investigated the loss of heterozygosity in tumours and survival in these patients.
Materials & Methods/Results
DNA from formalin fi xed tumour tissue was available from patients A, B, D, E, and F. Four microstaellite markers (D13S260, D13S171, D13S267 and D13S1493) within and fl anking the gene were typed on the 5 tumours using an ABI 377 Genetic Analyser. 'Peak height' of the alleles was used to determine the ratio of allelic loss compared to either genomic DNA or adjacent normal tissue from the paraffi n blocks. When informative markers (minimum 2 of 4) were averaged for each patient, the LOH rates were 77%, 87%, 97%, 77% and 81% respectively. DNA from the tumour samples was sequenced in order to determine which allele had been lost; patients B and F had lost the mutant allele, whilst patients A, D and E lost the wild type allele. The signifi cance of the loss of the mutant allele is not known, however loss of the wild type allele in three of fi ve tumours is consistent with a tumour suppressor model and indicative of a causal relationship between the BRCA2 germline mutations and predisposition to prostate cancer in these individuals. Survival details were available on the six mutation carriers as well as on 168 of early onset patients in whom no germline BRCA2 mutation was found. All six mutation carriers died within 75 months of diagnosis. The median survival time, by Kaplan-Meier estimates, for the 168 patients (of whom 113 were alive and 55 were deceased) at the time of censoring was 116 months, whilst in contrast, the median survival of the six mutation carriers was signifi cantly less at 48 months (log rank p=0.0004).
Conclusion
This observation is indicative that BRCA2 germline mutations are associated with early onset prostate cancer of a more aggressive phenotype.
Introduction
Lignocaine Periprostatic nerve block (PPNB) is routinely used for pain control during Prostatic TRUS biopsy. However, patients do report pain later through the day requiring additional analgesics. As the pain felt from the prostate gland is a visceral pain, we hypothesised that the systemic effects of diclofenac sodium should provide signifi cant benefi t to these patients.
Objectives
To assess the three regimes of pain relief (Lignocaine PPNB, Rectal Diclofenac or a combination of the two) both during and after the TRUS biopsy. Patients and methods 165 patients were randomised into three groups of 55 each to receive one of three methods of pain relief. A 12 core biopsy was performed in all the patients. The patients recorded the pain/ discomfort felt due to the presence of the probe, during biopsy, at one hour after the procedure, in the evening and the day following the biopsy on a visual analogue scale ranging from 0 to 10. .
Results
The pain scores recorded by the combination group, due to the biopsy (p<0.05) and in the evening of the procedure (p<0.001), were signifi cantly less than that of the other groups and the scores at one hour reached a near signifi cant value (p=0.062) There were no differences between the three groups as regards the pain/discomfort felt due to the presence of the probe or on the day after the procedure Conclusion Rectal diclofenac along with a periprostatic nerve block provides good and sustained pain relief for TRUS biopsy.
Maximising prostate cancer detection in repeat biopsy protocols
Joe Philip* Introduction Systematic 10-12 core prostatic biopsy protocols are standard in investigating men with a raised PSA. However, there is a lack of consensus regarding protocols for re-biopsy. We assessed cancer detection rates in an identical 12-core repeat biopsy protocol.
Patients and Methods
During a 4½-year period ending December 2003, 173 of 570 patients with persistently elevated age specifi c PSA between 2.5 and 10 ng/ml and initial benign biopsy were invited for repeat TRUS guided 12-core prostatic biopsy. The protocol for repeat biopsy was identical to the fi rst biopsy protocol, which included a peri-prostatic nerve block. First six biopsies were obtained from the periphery of the gland directed more laterally at the base, mid-zone and apices. The remainder were para-sagittal sextant biopsies. Pathological fi ndings were analysed on an individual core basis. Results Cancer was diagnosed in 39 patients (22.5%) on repeat biopsy. Men with cancer were older (p=0.001) with higher median Abstracts British Prostate Group PSA (p=0.41). Median Gleason score was 6 (6-9) with median number of cores positive for cancer being 2 (1-9). Maximal cancer detection rates were from peripheral mid-zones (33.3%) and peripheral apices (32.1%). Basal biopsies had the lowest detection rates (21.8% and 15.4%). Para-sagittal biopsies missed 36% of detected cancers. Patients with cancer also had signifi cantly lower prostate volumes (p<0.001) and higher PSA densities (p<0.001). Conclusion Low cancer yield from both peripheral basal and para-sagittal basal specimens on repeat biopsy indicates adequate sampling at initial biopsy. Maximal cancer yield in the peripheral midzones and apical zones suggests the necessity for concentrated sampling of these zones in repeat biopsy protocols. 
High
Introduction
Repeat biopsies in patients with high-grade PIN on prostate biopsies are often recommended. The pick up rate of cancer on repeat biopsies has been reported to be between 13 to 100%. The majority of these cancers represent tumours missed on the initial biopsies. The data on which a recommendation of repeat biopsy is based has been largely obtained from sextant biopsies performed in the non-screened setting. We set out to determine if this recommendation applied to patients undergoing an extended biopsy protocol who present through PSA screening. Method A single radiologist performed transrectal ultra sound guided extended protocol (at least 10 cores; sextant, lateral horn and medial) biopsies on 217 patients presenting with a raised PSA. Each individual biopsy sample was embedded in a single cassette and examined through three levels. All patients with high-grade PIN on the fi rst set of biopsies were offered a repeat procedure and the histological fi ndings in this group were analysed.
Results
The histological diagnosis on fi rst biopsy was benign in 49 patients (22.6%), isolated high-grade PIN in 55 patients (25.3%), atypical small acinar proliferation suspicious for cancer (including "PIN atypia") in 21 patients (9.7%) and adenocarcinoma in 92 patients (42.4%). 45 patients (81.8%) with high-grade PIN underwent re-biopsy. The histological diagnosis on the repeat biopsy was benign in 6 patients (13.3%), isolated high-grade PIN in 34 patients (75.6%), suspicious for cancer in 2 patients (4.4%) and adenocarcinoma in 3 patients (6.7%). Conclusion This study suggests that the incidence of prostate cancer on repeat biopsy in this group of men with isolated high-grade PIN on initial biopsy appears to be very low. It may therefore be appropriate to limit repeat biopsy to those men who have additional risk factors such as abnormal digital rectal examination, a rising serum PSA and/or abnormal free/total PSA ratio. We are grateful to the HTA NHS R&D and ProtecT PI's for including data from ProtecT Study patients in this work. 
Introduction
Metastatic prostate cancer, which is no longer sensitive to chemo-or anti-androgen therapy is the principle cause of death from this disease. Consequently, elucidation of the chemo and anti-androgen resistance mechanism(s) is urgently required. Interestingly, fi broblast growth factor 2 (FGF-2) can induce chemo-resistance to multiple agents including paclitaxel, doxorubicin, and 5-fl uorouracil in prostate cancer both in vitro and in vivo (Song et al. (2000) PNAS 97, 8658-8663) . However, the mechanism by which this is achieved is unknown. In small cell cancer cells, we have recently shown that FGF-2 also induces chemoresistance. The process is dependent on mitogen activated kinase kinase/extracellular regulated kinase (MEK/ Erk) signalling and is independent of phosphoinositol 3 kinase/ protein kinase B/ribosomal S6 kinase (PI3K/PKB/S6K1) pathway (Pardo et al. (2002) J.Biol. Chem. 277, 12040-12046.) . Furthermore, MEK/Erk induces increased expression of several anti-apoptotic proteins including Bcl-X L , Bcl-2, XIAP and cIAP1. Here, we investigate the mechanism of FGF-2-induced chemoresistance in prostate cancer cells. Materials and methods PC3 and LNCaP cell lines were maintained in RPMI medium and passaged using standard cell culture techniques. For experimental purposes, the cells were left in RPMI with 0.5% fetal calf serum overnight before being placed in serum-free medium prior to stimulation. The cells were then incubated with FGF-1, FGF-2 or epidermal growth factor (EGF) at various concentrations and times in the absence or presence of cell signalling inhibitors prior to lysis. The cell lysates were subjected to SDS-PAGE and western blotting with various antibodies including anti-FGF receptor 1 and 2, anti-phospho-Erk, -phospho-PKB, -phospho-S6K, -actin, -total Erk, -PKB, -S6K1 and -Bcl-X L .
Results
We initially confi rmed that FGF receptors 1 and 2 were expressed in PC3 and LNCaP cells. Dose response and time course studies revealed that 50ng/ml FGF-2 induced maximal phosphorylation of Erk at 5 min in PC3 cells but this effect was weak compared to 1 ng/ml EGF-induced Erk phosphorylation. In contrast, 50ng/ml FGF-2 induced strong S6K phosphorylation in these cells which was maximal after 10 min. In LNCaP cells 50ng/ml FGF-1 and FGF-2 for 5 min induced a much more prominent phosphorylation of Erk similar to that seen with 1 ng/ml EGF. FGF-1 and 2 also induced S6K phosphorylation in LNCaP cells similar to that seen in PC3 cells.
Conclusion
Our initial results indicate that PI3K/PKB/S6K1 signalling may play a role in FGF-2-mediated survival since Erk signalling is only weakly activated in PC3 cells. In LNCaP cells either MEK/ Erk or PI3K/PKB/S6K signalling may be important as FGF-2 induces both pathways. However, these are very preliminary data. Indeed, we are currently investigating whether FGF-2 in the absence or presence of various cell signalling inhibitors can block chemotherapy and ceramide-induced apoptosis in prostate cancer cells. We are also examining the effect of FGF-2 on expression of several anti-apoptotic proteins including Bcl-2, Bcl-X L and XIAP. 
Introduction
The type 1 insulin-like growth factor receptor (IGF1R) is overexpressed in prostate cancer. We recently described small interfering RNAs (siRNAs) that cause profound IGF1R gene silencing and impaired survival of prostate cancer cells in vitro. Since IGF signalling enhances apoptosis protection it follows that siRNA treatment may sensitise this notoriously chemoresistant tumour to cytotoxic drugs, many of which act through apoptosis induction. Previously we have shown that antisense-mediated IGF1R downregulation impairs the function of Atm, the protein product of the gene mutated in ataxia telangectasia. This protein is involved in detecting DNA damage, initiating repair and cell cycle checkpoint regulation, hence IGF1R gene silencing may preferentially sensitise to agents causing DNA damage.
Materials and Methods
We transfected IGF1R siRNAs or controls into three prostate cancer cell lines: DU145, PC3 and LNCaP. Cells were treated with drugs for 24 hours. We measured IGF1R levels by immunoblotting and survival by clonogenic assays. Response to double-strand (ds) DNA breaks induced by irradiation was assessed by pulsed-fi eld gel electrophoresis (PFGE), and cell cycle distribution by fl ow cytometry (FACS).
Results
Transfection with siRNAs inhibited IGF1R expression to 15-20% of control. These agents enhanced sensitivity to etoposide, mitoxantrone, nitrogen mustard and irradiation, with reduction in IC50 values in both DU145 and PC3 by factors of 1.5-2.5. There was no sensitization to paclitaxel or 5-fl uorouracil. Pulsed fi eld gel electrophoresis analysis suggested accumulation of DNA fragments less than 200kb following IGF1R silencing and irradiation, and FACS analysis of these same cells showed G2 cell cycle arrest. Conclusion IGF1R silencing by siRNA enhanced sensitivity to DNA damaging agents. The altered response to dsDNA breaks and G2 arrest after IGF1R silencing are consistent with a connection between IGF1R and Atm and a role for IGF signalling in the DNA damage response. These results support the concept of IGF1R targeting as novel therapy for advanced prostate cancer. 
Introduction
CD44 is a multifunctional cell surface adhesion molecule that has been implicated in tumour cell invasion and metastasis. In particular high molecular weight forms of CD44 show restricted expression in tumours and may correlate with tumour development and metastasis. Matrix metalloproteinases (MMPs) are involved tumour metastasis through the degradation of extracellular matrices (ECM). One such MMP is Membrane type-1 matrix metalloproteinase (MT1-MMP; also known as MMP-14) that cleaves a number of matrix proteins including collagen, fi bronectin, and vitronectin. MT1-MMP is known to convert pro-MMP-2 to active MMP-2 and cleave cell surface molecules such as CD44. Therefore we studied the role of CD44 variants and MT1-MMP in prostate cancer cell lines, the invasive PC-3, DU-145 and LNCaP, and two non-invasive prostate epithelial cell lines.
Material and Methods
RT-PCR, western blotting, tumour-endothelial adhesion assay, an in vitro endothelial invasion assay, dual-immunofl uorescence and laser scanning confocal microscopy were used to determine CD44 and MT1-MMP expression in the prostate cancer cell lines; DU-145, PC-3, LNCap.FGC, Ca-HPV-10 and Pz-HPV-7. Results RT-PCR revealed multiple isoforms of CD44 were expressed in PC-3, DU-145 and the two non-invasive cell lines. Direct DNA sequencing identifi ed both the standard and different variant isoforms in these cell lines. However, a high molecular weight isoform, CD44v3-10, was identifi ed only from the non-invasive cell lines but was completely absent in invasive PC-3, DU-145 and LNCaP. The other variants were similarly expressed in all cell lines tested. CD44v3-10 cDNA was isolated from the non-invasive epithelial cells and cloned into a mammalian expression vector before subsequent transfection into PC-3 cells. After culture these transformed cells, PC-NIVO, were selected for use in cell function assays. Results from a tumour-endothelial adhesion assay found PC-NIVO cells to be less adhesive to endothelial cells than wild-type PC-3 cells (p<0.005). Using a modifi ed in vitro endothelial invasion assay we showed a signifi cantly reduction in invasive potential of PC-NIVO compared to the wild-type PC-3 cells (p<0.005) and to PC-3 transfected with control plasmid (p<0.005). Western blot analysis revealed a reduction in MT1-MMP in PC-NIVO cells but not in wild type PC-3 and PC-3 transfected with control plasmid. The reduction of MT1-MMP was via a methylationindependent pathway as shown by a methylation specifi c PCR of the MT1-MMP promoter. Conclusion CD44v3-v10 isoform, which is expressed only in non-or lowinvasive prostate cancer cells, reduces adhesion and invasion of endothelium by prostate tumour cells possibly through negation of MT1-MMP function.
In vitro and in vivo study of a botanical isoprenoid, oridonin, on androgen-dependent and independent prostate cancer cell lines Sophie Chen 1,2 , Wei Jian
Introduction
In search of low toxicity anti-cancer compounds for treating advanced-stage prostate cancer, we isolated and investigated the biological activity of a botanical isoprenoid, oridonin. The compound was purifi ed from Rabdosia rubescens, which is a herb used in Northern China for treating esophageal cancer.
Materials and Methods
MTT cell viability assay was used to evaluate the antiproliferative activity of oridonin towards both of the androgen receptor positive (LNCaP) and negative (DU-145) prostate cancer cell lines. Fluorescence microscopy (FM) was used to observe the cell morphology of the cells. To further understand the mechanism of action, fl ow cytometric and Western blot analysis Abstracts British Prostate Group were employed to investigate the effect on cell cycle, protein expression of cancer suppressor gene (p53, Bax), and protooncogene (Bcl-2). Animal study with 50 Chinese Kun-Ming mice was performed to assess the acute toxicity (LD 50 ) of oridonin.
Results
Oridonin exhibited a potent activity in suppressing prostate cancer cell growth. The 50% inhibitory concentration (IC 50 ) determined by MTT was 8.3 ±1.0 and 5.8 ±2.3 µM for LNCaP and DU-145 respectively. FM examination revealed an increased frequency of apoptosis in both cell lines, with a more pronounced effect on DU-145, following exposure to equimolar concentration of oridonin. In contrast to its strong activity in suppressing cancer cell growth, the study showed a low toxicity of LD 50 (1.7g per kg body weight) in mice. The fl ow cytometric data further showed that oridonin induced a G 1 phase arrest in LNCaP (containing wt p53), while it blocked the cell cycle at G 2 M phase in DU-145 cells (containing mutated p53). This result is correlated well with the Western blot fi ndings that proteins of wt p53 and Bax were up-regulated and Bcl-2 was down-regulated in a dose-dependent manner.
Conclusion
Oridonin inhibits cancer cell-growth by inducing cell cycle arrest and shifting the balance between pro-and anti-apoptotic proteins in favor of apoptosis. The present data suggest that oridonin may be an interesting therapeutic candidate for advanced-stage prostate cancer due to its low toxicity. Further investigation of its potential benefi t is warranted.
The expression and regulation of ADAMTS-1, -4, -5, -9 and -15, and TIMP-3 by TGFbeta 1 in prostate cells:
Relevance to the accumulation of versican Cross, NA, Chandrasekharan, S, Jokonya, N, Hamdy FC, Buttle, DJ, Eaton, CL Academic Urology Unit, University of Sheffi eld, Royal Hallamshire Hospital, Sheffi eld S10 2RX Background Benign prostatic hyperplasia (BPH) is associated with an increase in the stromal compartment of the gland and in alterations to extracellular matrix components that have been associated with transforming growth factor (TGF) beta1 expression. Chondroitin sulphate proteoglycans are overexpressed in BPH and potentially contribute to disease pathology, although mechanisms controlling proteoglycan synthesis and degradation in the prostate are not clearly understood. A subgroup of the ADAMTS lineage of metalloproteases possess versican-degrading properties and are potential regulators of proteoglycan accumulation associated with BPH. These enzymes have one major inhibitor in the ECM, TIMP-3. Methods Prostatic stromal cells were cultured in the presence or absence of TGFbeta1. The effects of TGFbeta1 on mRNA expression were determined by Real-Time quantitative RT-PCR on gene expression using primers specifi c to ADAMTS-1, -4, -5, -9, -15, versican and TIMP-3. Baseline levels of ADAMTS and TIMP3 expression by qRT-PCR were also determined for the prostatic carcinoma cell lines PC3, DU145 and LNCaP. Results Prostatic stromal cell cultures consistently expressed ADAMTS-1, -4, -5, -9, -15 and TIMP-3. Conversely, expression of ADAMTS-4 and -5 was absent in the prostatic carcinoma cell lines PC3, DU145 and LNCaP, and only ADAMTS-15 was expressed by all three cell line. Only DU145 failed to express ADAMTS-1 however ADAMTS-9 was detected in this cell line and not in PC-3 or DU145. TIMP-3 was only detectable in LNCaP. In prostatic stromal cell cultures, TGFbeta1 resulted in a decrease in transcript level of ADAMTS-1, -5, -9 and -15 (5.8, 7.5, 3.3, 2.6-fold respectively (p<0.05)). Conversely, transcript levels for ADAMTS-4, versican and TIMP-3 were increased (3.6, 6.6, 7.6-fold respectively (p<0.05)).
Conclusions
The induction of versican expression by TGFbeta1 in BPH stromal cells is in agreement with histological studies on BPH. The negative effect of TGFbeta1 on ADAMTS-1, -5, -9 and -15 coupled with increases in their inhibitor, TIMP-3 may aid the accumulation of versican in the stromal compartment of the prostate in BPH. The selective induction of ADAMTS-4 mRNA expression by TGFbeta1 suggests that the gene for this enzyme contains unique controlling elements and suggests a distinct function for ADAMTS-4 in the prostate. 
Infrared (IR) Cytopathological Grading & Mass Spectral Imaging of Prostate Cancer
Introduction
Visual Gleason scoring of prostate cancer (CaP) has limitations with regards to its reproducibility / prognostication. IR spectroscopy measures the vibrational modes of biomolecules (phosphates, lipids, proteins and carbohydrates) as IR light is transmitted through micron scale areas of tissue. The IR spectrum is characteristic of the tissue's composition and in combination with neural network algorithms has been used to develop a molecular based classifi er to grade CaP tissue samples in an objective and reproducible manner. Additionally, time-offl ight secondary ion mass spectrometry (ToF-SIMS) has been used to acquire biochemical images of the PC-3 cell. This technique enables the localisation and identifi cation of target molecular and ionic species from the outermost layers of a submicrometer scale surface to be determined. Thus, enabling for the chemical analysis of different sections of a cell following freeze-fracture.
Materials and Methods
For the IR study, two serial sections from a paraffi n embedded specimen were collected. One was stained with H&E and Gleason scored by a consultant histopathologist (J.H.S). IR spectra were acquired from malignant locations using the second section. In total, 346 IR spectra were acquired from biopsies of 33 different patients. For the ToF-SIMS study, the PC-3 cell line was cultured onto silicon and fl ash frozen as a sandwich for freeze-fracture. This specimen was freeze-dried and analysed under vacuum in the ToF-SIMS instrument. Results A linear discriminant analysis (LDA) based diagnostic algorithm was constructed with IR spectra taken from biopsies of 4 patients, each exhibiting a different Gleason grade (2) (3) (4) (5) . IR spectra from the remaining 29 biopsies were used to blind test this model. The sensitivity and specifi city for the model to predict Gleason scores <7 were 70% and 89%, respectively; Gleason scores =7, 50% and 79%, respectively; Gleason scores >7, 65% and 83%, respectively. A correlation of IR-LDA score to the clinical stage of the tumour revealed that an IR-LDA score of ≥8 was associated with metastatic disease with a sensitivity and specifi city of 38% and 92%, respectively. Examination of the low sensitivity revealed that 86% of tumours assigned as Abstracts British Prostate Group IR-LDA score 8 with no metastasis, were T3 and T4 stage tumours and may indicate prognostic importance. ToF-SIMS analysis of the fractured PC-3 demonstrated localisation of K, Ca and Mg within the cytoplasm. Molecular fragments corresponding to different phospholipids were used to elucidate different fracture planes in the cell image. This allowed for confi rmation of Cu accumulation (associated with angiogenesis) within the cell cytoplasm and of lower concentrations in the basolateral leaf of the plasma membrane. Conclusions IR-LDA scoring of CaP tissue shows promise and needs to be assessed with a larger numbers of cases. ToF-SIMS imaging provides intercellular elemental ion localisations, (present at millimolar concentrations and vital to cell physiology) as well as lipidomic profi les.
An Anatomic study of human accessory cavernous Nerves P Jaiswal, A Chandra, V Sundaresan, P Dasgupta
Guys and St. Thomas Hospitals and GKT School of Medicine
Introduction
In addition to Walsh's neurovascular bundles a few animal studies have reported the presence of accessory cavernous nerves in relation to the anterior and lateral aspects of the prostate. Following traditional nerve sparing, the Detroit group has described preservation of the entire lateral pelvic fascia, the so-called "veil of Aphrodite" during robotic radical prostatectomy. We aim to quantify the location and size of cavernous nerves between the lateral pelvic fascia and prostatic capsule in humans.
Materials and Methods
Ten specimens from men (mean age 67, range 51 to 81) who had undergone non nerve-sparing radical cysto-prostatectomy were examined. Slides representing anterior and posterior halves of the prostate were viewed. Photomicrographs of the lateral pelvic fascia and prostatic capsule at magnifi cation of 4X were taken. The number and caliber of nerves present in the anterior and posterior sections were examined and compared using Simple PCI core software (Digital Pixel Ltd, England).
Results
The mean ± SEM number of nerves in the right posterior region were 33.6 ± 7.36 compared to 13.3 ± 2.13 in right anterior section. The mean number in the left posterior region were 20.7 ± 3.13 compared with 10.3 ± 2.73 in left anterior section. Thus 30% of cavernous neurons were located antero-laterally. The mean sizes of the anterior nerves were 209.7µ (range 40.8-709) and the posterior nerves 221.2µ (range 33.1-1156).
Conclusion
We provide an anatomic basis for better nerve-sparing during radical prostatectomy. Whether this will lead to improved potency rates merits further study.
Introduction
Apical dissection during radical prostatectomy affects the clinico-pathological outcome. Scardino used a fi ne, steel wire to retract the dorsal vein complex (DVC). Using real-time, per-operative trans rectal ultrasound imaging of the prostate, we demonstrate with digital video images, the per-operative landmarks of surgery and the anatomical basis for our low positive apical margin (14%) and very low urinary incontinence rates (6%).
Materials and Methods
At the time of radical prostatectomy, a bi-planar ultrasound transducer probe (B-K Medical type 8808) was inserted per rectally. Real-time images of the surgical procedure were obtained, correlated with steps in the anatomical dissection of the prostatic apex and histology. Results Per-operative TRUS of the prostate clearly demonstrated surgical landmarks. Colour fl ow doppler identifi ed the DVC. Tension on the steel wire arrested venous blood fl ow, distracting the DVC from the apex of the prostate and enabled a clean incision to be made in the DVC at the prostatic apex. With transection of the urethra the plane between Denonvilliers fascia and the anterior wall of the rectum could be demonstrated on ultrasound. Conclusion Ultrasound imaging during surgery can add invaluable anatomical detail and improves our understanding of surgical outcomes. Distraction of the DVC from the urethra and prostatic apex aids apical dissection, surgical margins and continence rates.
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Poster Presentations
Materials and Methods A review was made of 33 patients retrospectively who had received Mitoxantrone and Prednisolone at the Churchill hospital, and their response to treatment. They were then compared with the highly selected patients within the Tannock paper to assess applicability of the results to the Churchill population. Palliative endpoints reviewed included symptom control, with response defi ned as improvement in symptoms at two visits three weeks apart, or completion of a total of six to eight cycles of chemotherapy. PSA response was also examined. Results A total palliative response was seen in 38% of patients treated with Mitoxantrone and Prednisolone in the Tannock paper. Depending on the criteria utilised (improvement in symptoms or number of cycles) a palliative response was seen in 33 to 45% of patients treated at the Churchill Hospital. This correlates well with the results from Tannock et al. PSA response did not determine those patients who benefi ted from symptom reduction.
Conclusion
The signifi cant palliative response described requires a review of prescribing practice. Clinical governance is an area of paramount importance, diffi culties arise however in those areas where consensus guidelines are absent such as Hormone Resistant Prostate Carcinoma. Satisfactory care can be demonstrated however from comparison with seminal papers as is shown on this occasion. Introduction Psoriasin (S100A7) is a member of the S100 gene family that is involved in psoriasis and has been showed to be over expressed in cancer. This S100 protein family member is a calcium-responsive signalling molecule that is involved in cell cycle regulation and has also been implicated as a substrate for cell regulatory transglutaminases. However, the precise role of psoriasin in prostate cancer is still unknown. Hepatocyte growth factor/scatter factor (HGF/SF) is a motogen that causes a variety of biological responses in epithelial derived cells, including cell scattering through the activation of its tyrosine kinase receptor c-Met. This study sought to examine the level of psoriasin in prostate cancer cell lines after motogen-induced stimulation.
Is
Materials and Methods
Western blotting, Immunocytochemistry, cell scattering assay, Q-RT-PCR (real-time-quantitative PCR) and RT-PCR were used to assess the effects of HGF/SF at both the protein and mRNA levels in prostate cancer cells.
Results
At the protein level highly invasive prostate cancer cell lines (DU-145 and PC-3) had low levels of psoriasin expression. In contrast, low invasive cell lines (CAHPV10 and PZHPV7) had more intense staining of psoriasin especially at sites of tight 
Introduction
Finasteride has previously being shown to reduce haematuria of prostatic origin and blood loss during TURP. It has being shown to act, by reducing prostatic sub-urothelial microvessel density (MVD) and the expression of vascular endothelial growth factor (VEGF), which is a potent angiogenic stimulator, in the prostate. However, these results were after prolonged use of fi nasteride and we aimed to show that 2 weeks of fi nasteride would have a similar effect, confi rming observations that fi nasteride has a quick onset of action.
Materials and Methods
64 patients scheduled to undergo TURP were randomized to receive 5mg of fi nasteride or placebo daily for 2 weeks before surgery. Sections of prostatic urothelium were stained for VEGF expression and for CD31 to assess MVD. The analysis was assessed on 10 consecutive, non-overlapping high power fi elds and was performed in a blinded fashion. Results 31 received fi nasteride and 33 placebo. Both groups were similar in age, aspirin usage, PSA and the presence of a urethral catheter. Mean VEGF expression was signifi cantly lower in the fi nasteride group (47.1 ± 12.3) compared to controls (60.6 ± 19.2) (p<0.001). Similarly, mean MVD was signifi cantly lower in the fi nasteride arm (59.8 ± 12.9) than the control arm (70.7 ± 18.9) (p<0.01).
Conclusions
This study shows that fi nasteride, after only 2 weeks treatment, has a direct effect on the prostate, by inhibiting angiogenesis, which reduces the expression of VEGF and thus MVD.
Introduction
Prostate Carcinoma has previously been thought to be insensitive to chemotherapy. No chemotherapy regime is currently known to improve survival of patients with hormone resistant prostate cancer and there are no consensus guidelines. This combined with concerns about toxicity in patients with extensive bony disease and diffi culties with measuring a disease response by traditional radiographic criteria have led to a lack of interest in prescribing chemotherapeutic regimes. Tannock et al. performed a randomised trial in1996, demonstrating improved quality of life with chemotherapy, which has been of major importance in the management of these patients (Tannock et al. J of Clin Oncol 1996; 6:1756 -1764 . Our review aimed to establish evidence of a palliative benefi t in the population of patients receiving Mitoxantrone and Prednisolone at the Churchill Hospital Oxford.
Abstracts British Prostate Group cell-cell contact, or in tightly packed cell clusters. However, stimulation with the motogen HGF/SF (40ng/ml) increased the degree of cell scattering and reduced the level of psoriasin. The expression of psoriasin after stimulation by HGF/SF was assessed using RT-PCR and the quantity of their transcripts was determined using Q-RT-PCR. Addition of HGF/SF down regulated the level of psoriasin at the mRNA level (mean 2770 + sd 1725; copies/125ng of RNA vs. control 78940 + 107565).
Conclusion
Psoriasin is weakly expressed in highly invasive prostate cancer cells and is progressively lost with increased migration after motogen-induced stimulation. This study suggests that psoriasin may act as a migration and adhesion regulator in prostate cancer cells.
Introduction
Increasing awareness of prostate cancer has resulted in widespread PSA testing. We assessed age specifi c prostate cancer incidence and PSA assay patterns over the last fi ve years in Mid-Cheshire.
Material and Methods
Data from Mid-Cheshire Hospitals Trust between October 1998 and September 2003 were used. Age specifi c prostate cancer incidence and PSA testing patterns were recorded. Referral speciality, age specifi c raised levels, age of patients were assessed on a yearly basis.
Results
From October 1998 to September 2003, 28,070 PSA (25% raised for age) tests were assayed detecting biopsy proven cancers in 671 patients. Overall cancer incidence and number of PSA tests had doubled in the last fi ve years. In the 50-59yr and 60-69 yr age groups, though the number of PSA tests has doubled, cancer incidence has tripled. On the other hand, in the under 50yr age group there is no real increase in cancer detection rate. General Practitioners (GPs) now request 65% of the total PSA assays compared to 5 years ago.
Conclusion
In the 50-69 yr. age groups prostate cancer incidence has tripled suggesting that a corresponding increase in PSA testing in these age groups may result in an increased prostate cancer detection rate. In view of the low cancer incidence in men under 50 years, they may need more appropriate counselling before PSA testing. GPs ask for more than two-thirds of all PSA tests in this region and are best placed to implement these recommendations.
Introduction
Almost 40% of patients have locally advanced prostate cancer and high PSA values at presentation. These patients will undergo prostatic biopsy with its attendant complications for histological confi rmation before initiating treatment. We assessed accuracy of higher PSA values in diagnosing prostate cancer.
Patients and Methods
975 patients who underwent TRUS guided biopsy of the prostate for raised PSA (>2.5 ng/ml) over a 4½-year period ending December 2003 were considered for this study. They underwent a twelve-core protocol that included 6 peripheral biopsies. Patients were deemed unlikely to have prostate cancer only after two sets of negative twelve-core biopsies and a stable or decreasing PSA. 181 patients (19%) had PSA values above 20ng/ml. The accuracy of PSA alone in diagnosing prostate cancer was assessed in these patients. Results 461 patients were diagnosed with cancer while 514 had benign disease. Mean age of the patients was 68.6 years (range: 43-90 years). Men with cancer had higher median PSA in all groups. Positive predictive values were calculated for different cut-off PSA values, ranging from 0.93 at 50ng/ml to 0.96 at PSA of 140ng/ml.
Conclusion
Patients with higher PSA values (> 50) have a prostate cancer positive predictive value of 0.93+. We suggest that in patients with markedly elevated PSA (>50 ng/ml) and signifi cant co-morbidity, prostate biopsies may not be essential before initiating treatment.
National practice of PSA testing amongst hospital doctors S Gupta, IS Shergill, M Arya, HRH Patel Institute of Urology and Nephrology, UCL, London
Introduction
Recommendations for the use of the PSA blood test in the diagnosis of prostate cancer, and counselling prior to PSA testing have been issued. Despite these measures, PSA requests and counselling, amongst hospital doctors are thought to be inappropriate. We investigated the national practice of PSA testing amongst hospital doctors, outside the fi eld of urology, to assess these issues.
Patients and Methods
The use of PSA was assessed in 1500 hospital doctors, across 12 regions in the UK and Ireland, using a telephone questionnaire. Descriptive data were collected according to: medical speciality, indication for PSA testing, the role of PSA in diagnosing prostate cancer, counselling prior to PSA testing, and the response to abnormal PSA results. Results Out of 1500 hospital doctors questioned, 255 (17%) requested PSA. 42% actively arranged PSA screening, 97% requested PSA for LUTS, 98% in haematuria and 55% requested it in patients with unrelated symptoms. In diagnosing prostate cancer, 76% used PSA only. Prior to PSA testing, 66% counsel their patients, 42% discuss implications of an abnormal result and 4% discuss prostate cancer treatment. When a PSA test is abnormal, 85% refer directly to a urologist.
Conclusion
This study showed that the PSA blood test is inappropriately being used by hospital doctors outside the fi eld of urology and counselling prior to testing is poor. Currently available recommendations need better exposure to hospital doctors requesting the PSA blood test.
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An Artifi cial Neural Network to predict outcome of repeatIntroduction
There is both sparse and confl icting data in the literature regarding the peri-operative use of aspirin during urological surgery (Herget et al., Can Assoc Radiol J 1999; 50(3): 173-6, Connor and Wingate Clin Radiol 1999; 54(9): 598-603) . TRUS guided prostate biopsies used to diagnose prostate cancer, are likely to increase in number. Cancellation of the procedure for inadvertent use has staff time, cost and waiting list implications. However aspirin use may result in higher risk of post-procedure bleeding and hospitalization. Stopping aspirin prior to biopsies may result in an increased risk of thromboembolic events. We look to assess how Urologists in the United Kingdom manage patients on aspirin, attending for transrectal prostate biopsy. Methods A 10-point questionnaire was mailed to all Consultant Urologists in the United Kingdom, with the aim of establishing practices and protocols on the management of aspirin prior to prostate biopsy.
Results
There was a 48% response rate to the questionnaires. 44% of departments have protocols regarding aspirin use prior to prostate biopsies. 30% of Urologists stop aspirin prior to biopsies. 52% of these stop aspirin 1-week prior, 41% 2-weeks prior and 6% more than 2-weeks prior to the procedure. 33% of Urologists feel that aspirin increases bleeding complications and 6% of Urologists did not comment on this. 59% felt that the cerebrovascular risks of stopping aspirin outweigh the benefi t of stopping aspirin for bleeding. Only 4 consultants reported cerebrovascular side effects of stopping aspirin. For those who routinely stop aspirin the median time for restarting aspirin after the procedure was 2 days (range 0-10 days).
Conclusion
Urologists in the United Kingdom do not have a uniform approach to the management of aspirin prior to prostate biopsy. We recommend a randomized controlled study to establish evidence-based guidelines to ensure standardized practice. 
Invasive characterisitics of human prostatic epithelial cells
Introduction
Bone metastases are the major cause of morbidity and mortality for patients with prostate cancer. We have previously reported that prostate epithelial cells (PEC) isolated from both benign prostatic hyperplasia (BPH) and carcinoma of the prostate (CaP) patients bind preferentially to and at equivalent levels to bone marrow endothelium. However, only CaP epithelial cells have an invasive response towards bone marrow endothelium. The aim of this study was to analyse the invasive characteristics of malignant prostate epithelial cells.
Materials and Methods
Invasive responses of benign and malignant primary prostatic epithelial cells (PEC) and the PC-3 prostate cancer cell line, across Matrigel or BMEC Matrigel barriers, to various stimuli (tissue culture plastic, primary bone marrow endothelium, primary bone marrow stroma, prostatic fi broblasts, SDF-1) were studied using 8µm invasion chambers. Prostate epithelial cell binding to and invasion through bone marrow endothelium was followed in real time using confocal microscopy and image deconvolution.
Results
In an invasion chamber assay, bone marrow endothelium, bone marrow stroma and their extra cellular matrixes induced the migration of the malignant PC-3 cell line whilst the nonmalignant cell line PNT2-C2 demonstrated no invasive ability. Invasion chamber assays using primary BPH or CaP prostate epithelial cells showed that CaP epithelial cells were invasive, preferentially towards bone marrow stroma and prostatic fi broblasts, whilst BPH epithelial cells were non invasive. Blockade of the CXCR4 receptor with the specifi c peptide inhibitor T140 inhibited invasion towards bone marrow stroma and SDF-1. Confocal microscopy of PC3-GFP (GFP expressing) invasion through a bone marrow endothelial cell layer (BMECs) revealed that 80% of PEC cells bound within 60 minutes and all cells bound by 90 minutes. Binding and invasion occurred at the junctions between BMECs. Invasion through the BMECs was complete 182±43 minutes post binding.
Conclusion
We have shown that both bone marrow endothelium and stroma induced malignant prostate epithelial cells to invade. Binding Abstracts British Prostate Group and invasion occurred at the cellular junctions between bone marrow endothelial cells, with the invasive process taking approximately 180 minutes. These assays have been utilised to show that the peptide inhibitor of CXCR4, T140, is a potent inhibitor of prostate epithelial cell invasion. Further application of the techniques described here will provide greater insight into the mechanisms involved in the prostate cancer invasion and metastasis.
Introduction
We assess the effect of brachytherapy on potency and quality of life in a prospective, patient administered questionnaire study. Methods Patients completed the International Index of Erectile Function (IIEF-5) prior to brachytherapy and at 6 weeks, 3,6,9,12,18 and 24 months post implant. Patients who considered that they had erectile problems completed the ED effect on Quality of Life (EDQol) questionnaire. Men with an IIEF-5 score of <12/25 (moderate-severe ED) were considered impotent. Results 153 patients completed baseline and >1 postimplant IIEF-5 questionnaire, 39%(n=60) were potent pre-implant. 67% of potent patients maintained potency at last follow up (mean FU 15m). Potency rates improved over time postimplant 6wk-47%, 3m-56%, 6m-48%, 9m-63%, 12m-56%, 18m-75%. Of 93 patients impotent at baseline 63% completed the EDQuol; 15% reported no effect on quality of life, 39% mild effect, 30% moderate effect and 16% a severe effect. In patients who were impotent as a result of treatment at the 6 month assessment 88% completed EDQuol; 7% had no effect on quality of life, 47% mild effect, 27% moderate effect and 20% a severe effect. Conclusion Early potency after brachytherapy is encouraging and compares favourably with other modalities for the treatment of early prostate cancer. ED improves with time post-brachytherapy within the fi rst 18 months. Patients experiencing impotence as a result of treatment are equally likely to report moderatesevere ED effects on quality of life as those impotent before brachytherapy.
The Gleason grade of prostate cancer is an important pretreatment prognostic indicator and is incorporated into the Seattle risk cohort groupings (SRG) that also includes PSA and clinical stage to establish treatment strategy. This study examined whether any differences existed in the Gleason scoring between pathologists and what effect this would have had on treatment received. Methods Prostate cancer patients referred for brachytherapy had their biopsies reviewed by a reference pathologist (PD). We compared the agreement between the scoring of the distant pathologists with that of PD and evaluated if any differences changed the SRG. 
Results
In
Purpose
We describe the culture in vitro of explants from patients with malignant prostatic carcinoma. The purpose was: 1) to maintain ex vivo integral tissue including intact stromal and glandular elements in a three-dimensional (3D) microenvironment for long time (up to 2-3 weeks); 2) to investigate the behaviour of the different cellular types contained in the fragment during organ culture; 3) to describe the progression or regression of pathological changes in the fragment as a function of time in culture.
Materials and Methods
Tissue fragments (1-3mm 3 ) were cultured on gelatin sponges for several weeks and the viability, proliferation, migration and differentiation of epithelium were studied. Epithelial cells in these fragments could be well investigated at different time intervals in long-term culture and analysed by histology and immunohistochemistry using multiple specifi c markers on consecutive sections of the fragment. In particular, the following markers were used: p63, for epithelial progenitor cells; Ki-67, for proliferating cells; PSA, for prostatic luminal cells; HMwCK (CK1, CK5, CK10, CK14), for basal cells; androgen receptor (AR) , for luminal cells, endothelin-1 for prostatic secretory and endothelial cells, granulocyte macrophage-colony stimulating factor, for myeloid/ epithelial/ endothelial cells. Results Both normal and tumoural glands could be successfully maintained with preservation of structures as prior to culture, up to at least 14 days. After 7 days, a progressive hyperplasia of basal cells (HMwCK +), lining the surface of the fragment and migrating to the underlying sponge, was usually observed. Morphological evidence of frank glandular tumoural changes commonly found in association with cancer could be well identifi ed within the fragment. Additionally, after 7-14 days, in several cases, nests of cancerous cells (AR +, HMwCK -) became often detected peripherally on the fragment surface.
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Introduction
Cystectomy has been traditionally used in patients with high grade invasive bladder cancer. The long term survival for such patients is mixed. If an incidental prostate cancer was found it was only of academic interest. With better morbidity and mortality rates and better quality of life with orthotopic reconstructions, cystectomy is now being used in lower stage bladder cancer. The long term survival for these patients is much better. Prostate preservation at cystectomy has been reported. In these men incidental prostate cancer may be important.
Materials and Methods
We have analysed the results of all cystectomies performed in our unit between 1/3/97 and 30/10/03. All men had a cystoprostatectomy with no attempt to preserve the prostate. We have analysed our results looking specifi cally for incidental prostate cancer. Results 223 cystectomies were performed; 134 on men. 21 (16%) had incidentally found prostate cancer, and a further 5 high grade PIN. 14 had low grade (Gleason score 6 or less), 5 moderate grade (Gleason 7) and 2 high grade prostate cancer (Gleason 8 or higher).
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Pre cystectomy PSA was available in 7 men, in each case it was <10. Post cystectomy PSA was available in 11 men. It was still detectable (>0.1) in 3 men suggesting residual prostatic tissue.
Conclusions
In our series 16% of men having cystectomies have prostate cancer found incidentally. Up to a third still have detectable PSA post operatively, suggesting residual of prostatitic tissue. We would recommend preoperative PSA in all men prior to cystectomy.
